Wednesday, June 21, 2023

8:00 Welcome & Introductions
Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:30 Respiratory Syncytial Virus Vaccines - Adult
- Introduction
  Dr. Camille Kotton (ACIP, WG Chair)
- Manufacturer presentation: Pfizer season 2 safety &
efficacy; coadministration with influenza vaccine
  TBD (Pfizer)
- Manufacturer presentation: GSK season 2 safety &
efficacy; coadministration with influenza vaccine
  TBD (GSK)
- Updated cost-effectiveness of the Pfizer and GSK
  vaccines (main CDC model)
  Dr. David Hutton (University of Michigan)
- Comparison of cost effectiveness results of the main
  CDC model and each manufacturer model (Pfizer &
  GSK)
  Dr. Ismael Ortega Sanchez (CDC/NCIRD)
- Updated Evidence to Recommendations (incl. GRADE)
  and clinical considerations for 2 vaccines (Pfizer &
  GSK)
  Dr. Michael Melgar (CDC/NCIRD)

11:30 Break

11:45 Polio Vaccine
- Introduction
  Dr. Oliver Brooks (ACIP, WG Chair)
- Recommendations for Adult Polio Vaccination
  Dr. Sarah Kidd (CDC/NCIRD)

1:15 Break

2:00 Influenza Vaccine
- Introduction
  Dr. H. Keipp Talbot (ACIP, WG Chair)
- WG considerations and proposed recommendations
  Dr. Lisa Grohskopf (CDC/NCIRD)

4:00 Break

4:15 Public Comment

4:35 VOTES
- RSV Adult
- Polio
- Influenza

5:30 Adjourn
Thursday, June 22, 2023

8:00  Welcome & Introductions
      Dr. Grace Lee (ACIP Chair)
      Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:35  Agency Updates
      CDC, CMS, FDA, HRSA, IHS, OIDP, NIH

8:55  Pneumo Vaccines
      Introduction
      Economic analysis and public health impact of PCV20 use in children
      Comparison of cost-effectiveness analyses on PCV20 use in children
      Summary of WG interpretation on EtR and policy
      Dr. Kathy Poehling (ACIP, WG Chair)
      Dr. Charles Stoecker (Tulane University)
      Dr. Ayabina Diepreye (CDC/NCIRD)
      Dr. Miwako Kobayashi (CDC/NCIRD)

10:25 Break

10:40 Dengue Vaccines
      Introduction
      Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico
      Cost effectiveness analysis for TAK-003 – CDC model and comparison to manufacturer model
      Partial EtR (including GRADE) for TAK-003 – problem, benefits and harms, resource use
      Dr. Wilbur Chen (ACIP, WG Chair)
      Guido Espana
      Kaul Rajreni (CDC/NCIRD)
      Dr. Laura E Adams (CDC/NCEZID)

11:40 Break

12:25 Chikungunya Vaccine
      Introduction
      Chikungunya vaccine among U.S. travelers and healthcare providers
      Chikungunya virus infection among laboratory workers
      Update on large chikungunya outbreak in Paraguay
      Workgroup considerations
      Dr. Beth Bell (ACIP, WG Chair)
      Ms. Nicole Lindsey (CDC/NCEZID)
      Dr. Susan Hills (CDC/NCEZID)
      Dr. Susan Hills (CDC/NCEZID)
      Dr. Susan Hills (CDC/NCEZID)
      Dr. Susan Hills (CDC/NCEZID)

1:25 Break

1:40 Respiratory Syncytial Virus Vaccines - Pediatric/Maternal
      Introduction
      CDC model cost-effectiveness of Pfizer maternal RSVpreF vaccine
      Comparison of manufacturer and CDC cost-effectiveness models of Pfizer maternal RSVpreF vaccine
      Pfizer maternal RSVpreF vaccine evidence to recommendations (EtR), and clinical considerations
      Comparison of cost-effectiveness analyses for nirsevimab and Pfizer maternal RSVpreF vaccine
      Combined clinical considerations for use of nirsevimab and Pfizer maternal RSVpreF vaccine
      Dr. Sarah Long (ACIP, WG Chair)
      Dr. David Hutton (University of Michigan)
      Dr. Ismael Ortega Sanchez (CDC/NCIRD)
      Dr. Katherine Fleming-Dutra (CDC/NCIRD)
      Dr. David Hutton (University of Michigan)
      Dr. Jefferson Jones (CDC, NCIRD)

4:40 Break

4:50 Public Comment

5:10 VOTES

Pneumococcal
      Dr. Jeanne Santoli (CDC/NCIRD)

5:30 Adjorn
Friday, June 23, 2023

8:00  Welcome & Introductions  Dr. Grace Lee (ACIP Chair)

8:10  Mpxox Vaccine
     Introduction  Dr. Pablo Sanchez (ACIP, WG Chair)
     Epidemiology update  Dr. Faisal Minhaj (CDC/NCEZID)
     Vaccine effectiveness update  Dr. Ian Kracalik (CDC/NCEZID)
     Clinical considerations for use of JYNNEOS during mpxox outbreaks  Dr. Agam Rao (CDC/NCEZID)

10:10  Break

10:20  Meningococcal Vaccines
     Introduction  Dr. Kathy Poehling (ACIP, WG Chair)
     Cost effectiveness analysis  Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
     GRADE/EtR  Dr. Sam Crowe (CDC/NCIRD)
     Summary and workgroup considerations  Dr. Sam Crowe (CDC/NCIRD)

11:35  Break

11:45  Vaccine Safety  TBD

12:30  Break

12:40  COVID-19 Vaccines
     Introduction  Dr. Matthew Daley (ACIP WG Chair)
     COVID-19 epidemiologic data for populations of focus  TBD
     Infection-induced and hybrid immunity  Dr. Jefferson Jones (CDC/NCIRD)
     COVID-19 vaccine effectiveness updates  Dr. Ruth Link-Gelles (CDC/NCIRD)
     Summary and work group considerations  TBD

2:40  Adjourn

Acronyms
CDC  Centers for Disease Control and Prevention
CMS  Centers for Medicare and Medicaid Services
COVID-19  Coronavirus disease 2019
EtR  Evidence to Recommendations Framework
FDA  Food and Drug Administration
GRADE  Grading of Recommendations Assessment, Development and Evaluation
HRSA  Health Resources and Services Administration
IHS  Indian Health Service
NCHHSTP  National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD  National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID  National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID  National Institute of Allergy and Infectious Diseases
OIDP  Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2  Severe Acute Respiratory Syndrome Coronavirus 2

WG  Work Group
WHO  World Health Organization
VE  Vaccine Effectiveness